Summary
Abbott Laboratories (ABT) filed an 8-K on July 20, 2022, to announce its second quarter 2022 financial results. The filing primarily furnished a press release detailing these results. Investors should note that Abbott utilizes non-GAAP financial measures in its reporting, which exclude items such as acquisition-related expenses, restructuring costs, voluntary recall expenses, and certain litigation and tax items. The company asserts that these non-GAAP measures provide greater visibility into ongoing business performance and are used internally for performance assessment.
Key Highlights
- 1Abbott Laboratories reported its Q2 2022 financial results on July 20, 2022.
- 2The results were presented via a press release furnished as an exhibit to the 8-K filing.
- 3The company employs non-GAAP financial measures to report its performance.
- 4Non-GAAP measures exclude items like acquisition costs, restructuring expenses, voluntary recall costs, and certain litigation/tax adjustments.
- 5Abbott's management believes these non-GAAP measures offer a clearer view of ongoing operational performance.
- 6Investors are advised to consider non-GAAP measures alongside GAAP measures.